Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 26 Sarcoma 16 Neoplasm Metastasis 12 Carcinoma, Non-Small-Cell Lung 9 Ovarian Neoplasms 8 Breast Neoplasms 8 Recurrence 6 Neoplasms 5 Melanoma 4 Liposarcoma 4 Leiomyosarcoma 4 Glioblastoma 4 Fallopian Tube Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Neuroendocrine Tumors 3 Lung Neoplasms 3 Kidney Neoplasms 3 Hemangiosarcoma 3 Gastrointestinal Stromal Tumors 3 Thyroid Neoplasms 2 Thyroid Carcinoma, Anaplastic 2 Sarcoma, Synovial 2 Sarcoma, Alveolar Soft Part 2 Rhabdomyosarcoma 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Gliosarcoma 2

Interventions

Imatinib Mesylate 4 Gemcitabine 2 Doxorubicin 2 Docetaxel 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 saracatinib 1 pembrolizumab 1 pazopanib 1 envafolimab 1 TTI-621 1 Sunitinib 1 Razoxane 1 Radiotherapy, Intensity-Modulated 1 Radiation Dose Hypofractionation 1 Quality of Life 1 Polymerase Chain Reaction 1 Neoadjuvant Therapy 1 MLN 8237 1 Ipilimumab 1 Gene Expression Profiling 1 Dexrazoxane 1 Dactinomycin 1 Blotting, Western 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Dermatofibrosarcoma × pazopanib × Clear all

NCT01059656 2016-07-01

DFSP-PAZO

Assistance Publique - Hôpitaux de Paris

Phase 2 Terminated

Dermatofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡